By following this link you will be leaving a Takeda controlled website for a third party website
Please note that Takeda is not responsible or liable for any third party website and the website may not be appropriate for all audiences
If you're looking for information on patient savings,
you've come to the right place. Have a look below at the
various savings and support programs that Motegrity has to offer.
Maintain their momentum
available in a 90-day supply
With the Motegrity savings card, eligible patients may
pay as little as $15 per 30-day or 90-day prescription.*
A 90 day prescription means fewer pharmacy visits to help
your patients maintain their momentum between office visits.
* Up to $90 max benefit per 30-day prescription; $325 max benefit per 90-day prescription. Terms and conditions apply. Click here for more details.
* Up to $90 max benefit per 30-day prescription; $325 max benefit per 90-day prescription. Terms and conditions apply. Click here for more details.
Did you know?
Patients can add the Motegrity Savings Card to the Mobile Wallet on their phone and use it at the pharmacy.
Interested in receiving samples of Motegrity?
Your patients can benefit from a trial. Order a 7-day sample to get started.
Please note that Takeda is not responsible or liable for any third party website and the website may not be appropriate for all audiences
Eligible Commercially Insured patients may pay as little as $15 and receive up to $90 off their co-pay or out of pocket expenses per 30 day supply of Motegrity® (prucalopride). Offer is tiered based on quantity dispensed:
Tier 1: 1-30 tablets; Patient pays $15, up to max $90 benefit for 1 use ($2700 lifetime)
Tier 2: 31-60 tablets; Patient pays $15, up to max $180 benefit for 2 use(s) ($2700 lifetime)
Tier 3: 61-90 tablets; Patient pays $15, up to max $325 benefit for 3 use(s) ($3250 lifetime)
Offer valid for up to 30 uses through offer expiry. A valid Prescriber ID# is required on the prescription. Offer valid for patients ages 18 and older. Offer not valid for cash paying patients.
Restrictions: This offer is valid in the United States, Puerto Rico, and the U.S. Territories. Offer not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, Tricare, or other federal or state health programs (including any state medical assistance program) or where prohibited by the health insurance provider. Cash Discount Cards and other non-insurance plans are not valid as primary under this offer. If the patient is eligible for drug benefits under any such program, the patient cannot use this offer. By using this offer, the patient certifies that he or she will comply with any terms of his or her health insurance contract requiring notification to his or her payor of the existence and/or value of this offer. Offer not valid for patients under 18 years of age. It is illegal to (or offer to) sell, purchase, or trade this offer. This offer is not transferable and is limited to one offer per person and may not be combined with any other coupon, discount, prescription savings card, rebate, free trial, patient assistance, or other offer. Not valid if reproduced. Void where prohibited by law. Program managed by ConnectiveRx on behalf of Takeda Pharmaceuticals U.S.A., Inc. The parties reserve the right to discontinue, rescind, revoke or amend this offer without notice at any time. This is not health insurance.
Please expand for Indication and Important Safety Information.
Contraindications
Warnings and Precautions
Suicidal Ideation and Behavior: In clinical trials, suicides, suicide attempts and suicidal ideation have been reported. Postmarketing cases of suicidal ideation and behavior as well as self-injurious ideation and new onset or worsening of depression have been reported within the first few weeks of starting Motegrity. A causal association between treatment with Motegrity and an increased risk of suicidal ideation and behavior has not been established. Monitor patients for new onset or worsening of depression and emergence of suicidal thoughts and behavior. Instruct patients to discontinue Motegrity immediately and contact their healthcare provider if they experience any of these symptoms.
Adverse Reactions
Most common adverse reactions (≥2%) are headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, and fatigue.
Use in Specific Populations
INDICATION
Motegrity® (prucalopride) is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
Please click here for full Prescribing Information.
THIS SITE IS INTENDED FOR U.S. HEALTHCARE PROFESSIONALS ONLY
©2024 Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421. All rights reserved. 1-877-TAKEDA-7 (1-877-825-3327). MOTEGRITY® and the MOTEGRITY Logo® are registered trademarks of Takeda Pharmaceuticals U.S.A., Inc. TAKEDA and the TAKEDA logo are registered trademarks of Takeda Pharmaceutical Company Limited. US-PRU-0728v4.0 11/24.
All content of this website, including text, images, graphics, sound files, and their arrangement, is copyrighted and owned by Takeda and is protected by international copyright laws. All other intellectual property rights are reserved. The content may not be copied for commercial use or distribution, nor may these objects be downloaded, modified, or posted to other sites. This site is intended solely for US residents and is governed solely by US laws and government regulations. Please see our Legal Notice for more information. While Takeda makes reasonable efforts to include accurate, up-to-date information on this site, Takeda makes no warranties or representations as to its accuracy. Takeda assumes no liability for any errors or omissions in the content of this site. The information on this site is not intended to make a diagnosis or to take the place of talking to a US health care professional.
Contraindications
Warnings and Precautions
Suicidal Ideation and Behavior: In clinical trials, suicides, suicide attempts and suicidal ideation have been reported. Postmarketing cases of suicidal ideation and behavior as well as self-injurious ideation and new onset or worsening of depression have been reported within the first few weeks of starting Motegrity. A causal association between treatment with Motegrity and an increased risk of suicidal ideation and behavior has not been established. Monitor patients for new onset or worsening of depression and emergence of suicidal thoughts and behavior. Instruct patients to discontinue Motegrity immediately and contact their healthcare provider if they experience any of these symptoms.
Adverse Reactions
Most common adverse reactions (≥2%) are headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, and fatigue.
Use in Specific Populations
INDICATION
Motegrity® (prucalopride) is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
Please click here for full Prescribing Information.
Please note that Takeda is not responsible or liable for any third party website and the website may not be appropriate for all audiences.